This public procurement record has 12 releases in its history.

AwardUpdate

16 Dec 2024 at 11:04

AwardUpdate

16 Dec 2024 at 11:03

AwardUpdate

16 Dec 2024 at 11:02

AwardUpdate

16 Dec 2024 at 11:01

AwardUpdate

16 Dec 2024 at 11:00

AwardUpdate

16 Dec 2024 at 10:59

AwardUpdate

16 Dec 2024 at 10:58

AwardUpdate

16 Dec 2024 at 10:56

AwardUpdate

16 Dec 2024 at 10:50

AwardUpdate

13 Dec 2024 at 15:44

Award

22 Jul 2021 at 16:00

Tender

22 Jan 2021 at 11:50

Summary of the contracting process

NHS England has announced an extension and modification of their NHS Framework Agreement for the supply of Human Normal Immunoglobulin and Anti-D Immunoglobulin. The framework agreement, originally commencing on July 1st, 2021, and set to end on March 31st, 2025, has been extended by 3 months for IVIg products (Lots 1, 2, 5, and 6) until September 30th, 2025, and by 6 months for SCIg products (Lots 3 and 7) until December 31st, 2025. This adjustment aligns with ongoing efforts to transition patients from products supplied by certain suppliers not secured under a new framework to those guaranteed by new suppliers. Additionally, the estimated value of the framework agreement is being increased from £1.2bn to £1.6bn, reflecting higher demand and price adjustments due to inflation and rebate schemes.

This tender creates substantial opportunities for suppliers within the pharmaceutical industry, particularly those specialising in immunoglobulin products. Companies capable of ensuring continuous supply and managing product transitions will find this an advantageous proposition. Both large enterprises and SMEs with robust supply chain capabilities are well-suited to compete, especially amid the increased framework value and extension, which highlights NHS England’s reliance on reliable pharmaceutical partners to ensure the uninterrupted supply of critical immunoglobulin products to healthcare providers.

How relevant is this notice?

Notice Title

NHS Framework Agreement for the supply of Human Normal Immunoglobulin and Anti-D Immunoglobulin

Notice Description

National Framework Agreement for the supply of Human Normal Immunoglobulin and Anti-D Immunoglobulin. The framework will commence on 1 July 2021 for a period of 18 months with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for a list of the purchasing points.

Lot Information

Lot No: 1-9

NHS Framework Agreement for the supply of Human Normal Immunoglobulin and Anti-D Immunoglobulin. The framework will commence on 1 July 2021 for a period of 18 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.

Lot 1 - 5% Intravenous Immunoglobulin (5% IVIg)

This modification notice is to provide notice of the modification of the framework agreement (as defined below) to (i) extend its duration with a limited number of suppliers and (ii) increase the estimated value of the framework agreement across all lots.
The modification is further described in sections VII.2.1 and VII.2.2 below, but in short NHS England were required to (i) modify the Current Framework with the Absent Suppliers (as defined below) so as to extend the Current Framework for those Absent Products (as defined below) for a further period of (i) 3-months for IVIg products (Lots 1, 2, 5 and 6) (so to 30th September 2025) and (ii) 6-months for SCIg products (Lots 3 and 7) (so to 31st December 2025) and (ii) increase the estimated value of the Current Framework from PS1.2bn to PS1.6bn (an increase of 33%).

Options: option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months

Lot 2: 10% Intravenous Immunoglobulin (10% IVIg)

10% Intravenous Immunoglobulin (10% IVIg)

Options: option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months

Lot 3: Subcutaneous Immunoglobulin (SCIg)

Subcutaneous Immunoglobulin (SCIg)

Options: option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months

Lot 4: Facilitated Subcutaneous Immunoglobulin (fSCIg)

Facilitated Subcutaneous Immunoglobulin (fSCIg)

Options: option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months

Lot 6: 10% Intravenous Immunoglobulin (10% IVIg)

10% Intravenous Immunoglobulin (10% IVIg)

Options: option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months

Lot 5: 5% Intravenous Immunoglobulin (5% IVIg)

5: 5% Intravenous Immunoglobulin (5% IVIg)

Options: option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months

Lot 7: Subcutaneous Immunoglobulin (SCIg)

Subcutaneous Immunoglobulin (SCIg)

Options: option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months

Lot 9: Anti-D Immunoglobulin (Anti-D)

Anti-D Immunoglobulin (Anti-D)

Options: option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months

Lot 8: Facilitated Subcutaneous Immunoglobulin (fSCIg)

Facilitated Subcutaneous Immunoglobulin (fSCIg)

Options: option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months

Publication & Lifecycle

Open Contracting ID
ocds-h6vhtk-028c7b
Publication Source
Find A Tender Service
Latest Notice
https://www.find-tender.service.gov.uk/Notice/040406-2024
Current Stage
Award
All Stages
Tender, Award

Procurement Classification

Notice Type
Tender Notice
Procurement Type
Framework
Procurement Category
Goods
Procurement Method
Open
Procurement Method Details
Open procedure
Tender Suitability
Not specified
Awardee Scale
Large, SME

Common Procurement Vocabulary (CPV)

CPV Divisions

33 - Medical equipments, pharmaceuticals and personal care products


CPV Codes

33651520 - Immunoglobulins

Notice Value(s)

Tender Value
£1,200,000,000 £1B-£10B
Lots Value
Not specified
Awards Value
Not specified
Contracts Value
£1,600,000,001 £1B-£10B

Notice Dates

Publication Date
16 Dec 20241 years ago
Submission Deadline
26 Feb 2021Expired
Future Notice Date
Not specified
Award Date
23 Jun 20215 years ago
Contract Period
1 Jul 2021 - 31 Mar 2025 3-4 years
Recurrence
Not specified

Notice Status

Tender Status
Complete
Lots Status
Active, Cancelled
Awards Status
Active
Contracts Status
Active

Contracting Authority (Buyer)

Main Buyer
NHS England
Additional Buyers

The NHS Commissioning Board (operating under the name of NHS England)

Contact Name
Available with D3 Tenders Premium →
Contact Email
Available with D3 Tenders Premium →
Contact Phone
Available with D3 Tenders Premium →

Buyer Location

Locality
LONDON
Postcode
SE1 8UG
Postcode Area
South East London
Country
England

Major Region (ITL 1)
TLI London
Basic Region (ITL 2)
TLI4 Inner London - East
Small Region (ITL 3)
TLI45 Lambeth
Delivery Location
Not specified

Local Authority
Lambeth
Electoral Ward
Waterloo & South Bank
Westminster Constituency
Vauxhall and Camberwell Green

Supplier Information

Number of Suppliers
8
Supplier Names

BIO PRODUCTS LABORATORY LIMITED

Bio Products Laboratory Ltd

Biotest UK Limited

CSL Behring UK Ltd

Grifols UK Ltd.

LFB

Octapharma Limited

Shire Pharmaceuticals Ltd

Open Contracting Data Standard (OCDS)

View full OCDS Record for this contracting process

JSON Markdown

The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.

Loading OCDS record...